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It is estimated that 1.8% of Americans have Hepatitis C antibodies and that about
74% of these individuals have chronic infection.1 These prevalence rates correlate
with 3.9 million and 2.7 million Americans, respectively. Hepatitis C will cause
cirrhosis in about 25% of patients with chronic infection, of whom 2% to 5% will
develop hepatocellular cancer each year.2 Chronic Hepatitis C results in
approximately 8,000 to 10,000 deaths per year in the United States.3,4 This number
is projected to triple by the year 2010.5
Recently, Hepatitis C has moved to the forefront of concerns within many managed
care organizations. The potential future healthcare burden of Hepatitis C is alarming.
Much of the available literature provides cost estimates of Hepatitis C extrapolated
from actuarial data. This is likely not reflective of the “true” cost of healthcare for
this population.
An analysis was conducted to identify all medical and pharmacy costs accrued during
1999 by members with Hepatitis C in a Philadelphia Medicaid managed care
organization (MCO). Hepatitis C-infected patients were identified from a database of
continuously enrolled members using ICD-9 codes indicative of Hepatitis C. Medical
and pharmacy claims for these identified members during the study period were
obtained and analyzed. Costs were reported as reimbursements paid for medical
claims and pharmacy claims. The analysis was not adjusted for disease severity. It
was approved by the IRB, and patient identifiers were blinded to assure patient
confidentiality.
From a cohort of 73,869 members, 395 members (0.535%) met inclusion criteria for
Hepatitis C. The mean age was 46.5 years (SD= 9.5, range= 4 - 81) and 213
(53.9%) were male. The 395 members had medical claims totaling $4,075,082. I n
p a t i e n t hospital services accounted for 48% of these costs. Further analysis
showed that patients with either a history of a t r a n s p l a n t or a transplant
procedure (=12) performed in 1999 h a d medical claims that totaled $600,445.
Inpatient claims for this group accounted for $497,594 of the total medical claims. In
addition, there was one significant patient outlier that had total medical costs of
$881,933. The majority of these costs were related to home care. These 13 patients
accounted for 36% of all medical costs for Hepatitis C members.
The following comorbid diagnoses accounted for a large number of the medical
claims among all identified Hepatitis C members: chronic renal failure (28 patients),
congestive heart failure (38 patients), human immunodeficiency virus (45 patients)
and pneumonia (44 patients). The total cost for claims for each of these diagnoses is
as follows: chronic renal failure ($330,882), congestive heart failure ($281,839),
human immunodeficiency virus ($153,406) and pneumonia ($138,871).
Pharmacy claims for all Hepatitis C members totaled $1,495,096. Based on number
of claims, the most common therapeutic areas prescribed included behavioral health,
cardiovascular and respiratory medications. Sixty patients had pharmacy claims for
combination therapy with ribavirin/interferon alfa-2b, and 25 patients had claims for
interferon monotherapy. Ten patients in this population had claims for both

Health Policy Newsletter Vol. 14, Number 4 (December 2001), Article 9

Amy L. Phillips: Healthcare Cost of Hepatitis C-infected Members in a MCO
monotherapy and combination therapy during 1999. Pharmacy claims related to
treatment for Hepatitis C totaled $437,735.
Total healthcare costs (combined medical and pharmacy claims) to this Medicaid
MCO during 1999 for the 395 members identified with Hepatitis C exceeded $5.5
million. Additionally, Hepatitis C patients often have comorbid conditions, including
chronic renal failure or human immunodeficiency virus, or may undergo organ
transplantation, all of which can contribute to drastic increases in healthcare cost. In
conclusion, as the number of persons with Hepatitis C is expected to increase, the
overall cost of healthcare for these patients is likely to be significant.
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